Hans E. Huber

faculty photo
Adjunct Professor of Pharmacology
Associate Director, Center for Targeted Therapeutics and Translational Nanomedicine, Perelman School of Medicine
Department: Pharmacology

Contact information
213 Abbey Lane
Lansdale, PA
M.S. (Microbiology)
Swiss Federal Institute of Technology (ETH), Zürich, 1977.
Ph.D. (Biochemistry)
Swiss Federal Institute of Technology (ETH), Zürich , 1982.
Post-Graduate Training
Postdoctoral Fellow, Biozentrum, University of Basel, Switzerland , 1982-1984.
Research Fellow, Pharmacology, Harvard Medical School, Boston, 1985-1989.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Itmat Expertise

Targeted delivery of intracellular macromolecular therapeutics

Description of Other Expertise

Management of research collaborations and evaluation of licensing, investment and acquisition opportunities in the above areas.

Description of Research Expertise

Preclinical development of small molecules, antibodies and oligonucleotide therapeutics for oncology and other therapeutic areas. Targeted delivery of macromolecular therapeutics including nanoformulations and drug conjugates.

Selected Publications

Zhang, N et al: Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. mAbs 3: 289-298, 2011.

Cherrin C et al: An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol. Ther. 9: 493-503, 2010.

Aste-Amezaga, M et al: Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS ONE 5: e9094, 2010.

Cox C D et al: Kinesin spindle protein (KSP) inhibitors. J. Med. Chem. 51: 4239-4252, 2008.

She Q-B et al: Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3: e3065, 2008.

DeFeo-Jones D et al: Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. 4: 271-279, 2005.

Barnett S F et al: Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385: 399-408, 2005.

Yan Y et al: Inhibition of a mitotic motor protein: where, how, and conformational consequences. J. Mol. Biol. 335: 547-554, 2004.

Huber H E et al: Retinoblastoma protein reverses DNA bending by transcription factor E2F. J. Biol. Chem. 269: 6999-7005 1994.

Huber H E and Richardson C C: Processing of the primer for plus-strand DNA synthesis by HIV-1 reverse transcriptase. J. Biol. Chem. 265: 10565-10573 1990.

back to top
Last updated: 09/10/2019
The Trustees of the University of Pennsylvania